These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38780922)

  • 21. Forced into battle.
    Kaiser J
    Science; 2020 May; 368(6494):930-933. PubMed ID: 32467373
    [No Abstract]   [Full Text] [Related]  

  • 22. Bispecific Antibodies in Lymphoma - Another Win for T Cells.
    Bartlett NL
    N Engl J Med; 2022 Dec; 387(24):2285-2286. PubMed ID: 36507659
    [No Abstract]   [Full Text] [Related]  

  • 23. Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis.
    Reynolds G; Cliff ERS; Mohyuddin GR; Popat R; Midha S; Liet Hing MN; Harrison SJ; Kesselheim AS; Teh BW
    Blood Adv; 2023 Oct; 7(19):5898-5903. PubMed ID: 37467036
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Response to: Correspondence on 'Cardiovascular toxicities associated with bispecific T-cell engager therapy' by Noguchi
    Sayed A; Munir M; Poliner M; Sughra S; Epperla N; Addison D
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38649282
    [No Abstract]   [Full Text] [Related]  

  • 25. Bispecific T-Cell Engagers (BiTEs) as Treatment of B-Cell Lymphoma.
    Smits NC; Sentman CL
    J Clin Oncol; 2016 Apr; 34(10):1131-3. PubMed ID: 26884583
    [No Abstract]   [Full Text] [Related]  

  • 26. [Cancer therapy using bispecific antibodies].
    Kadowaki N
    Rinsho Ketsueki; 2018; 59(10):1942-1947. PubMed ID: 30305495
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tuning the potency and selectivity of ImmTAC molecules by affinity modulation.
    Robertson IB; Mulvaney R; Dieckmann N; Vantellini A; Canestraro M; Amicarella F; O'Dwyer R; Cole DK; Harper S; Dushek O; Kirk P
    Clin Exp Immunol; 2024 Feb; 215(2):105-119. PubMed ID: 37930865
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Translation and Clinical Development of Bispecific T-cell Engaging Antibodies for Cancer Treatment.
    Yuraszeck T; Kasichayanula S; Benjamin JE
    Clin Pharmacol Ther; 2017 May; 101(5):634-645. PubMed ID: 28182247
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Single cell-produced and in vitro-assembled anti-FcRH5/CD3 T-cell dependent bispecific antibodies have similar in vitro and in vivo properties.
    Ovacik AM; Li J; Lemper M; Danilenko D; Stagg N; Mathieu M; Ellerman D; Gupta V; Kalia N; Nguy T; Plaks V; David Johnson C; Wang W; Brumm J; Fine B; Junttila T; Lin K; Carter PJ; Prabhu S; Spiess C; Kamath AV
    MAbs; 2019; 11(2):422-433. PubMed ID: 30550367
    [TBL] [Abstract][Full Text] [Related]  

  • 30. T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals.
    Philipp N; Kazerani M; Nicholls A; Vick B; Wulf J; Straub T; Scheurer M; Muth A; Hänel G; Nixdorf D; Sponheimer M; Ohlmeyer M; Lacher SM; Brauchle B; Marcinek A; Rohrbacher L; Leutbecher A; Rejeski K; Weigert O; von Bergwelt-Baildon M; Theurich S; Kischel R; Jeremias I; Bücklein V; Subklewe M
    Blood; 2022 Sep; 140(10):1104-1118. PubMed ID: 35878001
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correspondence on 'Cardiovascular toxicities associated with bispecific T-cell engager therapy' by Sayed
    Noguchi Y; Yan M; Tachi T; Yoshimura T
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38649281
    [No Abstract]   [Full Text] [Related]  

  • 32. [Please a BiTE!].
    Freitag H; Gress G; Messer K; Sivaz G; Weinbender O; Zündorf I; Dingermann T
    Pharm Unserer Zeit; 2009; 38(5):396-8. PubMed ID: 19711314
    [No Abstract]   [Full Text] [Related]  

  • 33. Approaches to implement bispecific antibody treatment of ovarian carcinoma.
    Canevari S; Mezzanzanica D; Mazzoni A; Negri DR; Figini M; Ramakrishna V; Bolis G; Colnaghi MI
    Cancer Immunol Immunother; 1997; 45(3-4):187-9. PubMed ID: 9435870
    [No Abstract]   [Full Text] [Related]  

  • 34. Tumor-growth inhibition with bispecific antibody fragments in a syngeneic mouse melanoma model: the role of targeted T-cell co-stimulation via CD28.
    Grosse-Hovest L; Brandl M; Dohlsten M; Kalland T; Wilmanns W; Jung G
    Int J Cancer; 1999 Jan; 80(1):138-44. PubMed ID: 9935244
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bispecific antibodies in cancer therapy, from the laboratory to the clinic.
    Koelemij R; Kuppen PJ; van de Velde CJ; Fleuren GJ; Hagenaars M; Eggermont AM
    J Immunother; 1999 Nov; 22(6):514-24. PubMed ID: 10570750
    [TBL] [Abstract][Full Text] [Related]  

  • 36. T Cell-Redirecting Strategies to 'STAb' Tumors: Beyond CARs and Bispecific Antibodies.
    Blanco B; Compte M; Lykkemark S; Sanz L; Alvarez-Vallina L
    Trends Immunol; 2019 Mar; 40(3):243-257. PubMed ID: 30827461
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bispecific digoxigenin-binding antibodies for targeted payload delivery.
    Metz S; Haas AK; Daub K; Croasdale R; Stracke J; Lau W; Georges G; Josel HP; Dziadek S; Hopfner KP; Lammens A; Scheuer W; Hoffmann E; Mundigl O; Brinkmann U
    Proc Natl Acad Sci U S A; 2011 May; 108(20):8194-9. PubMed ID: 21536919
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor-targeted CD28 bispecific antibodies enhance the antitumor efficacy of PD-1 immunotherapy.
    Waite JC; Wang B; Haber L; Hermann A; Ullman E; Ye X; Dudgeon D; Slim R; Ajithdoss DK; Godin SJ; Ramos I; Wu Q; Oswald E; Poon P; Golubov J; Grote D; Stella J; Pawashe A; Finney J; Herlihy E; Ahmed H; Kamat V; Dorvilliers A; Navarro E; Xiao J; Kim J; Yang SN; Warsaw J; Lett C; Canova L; Schulenburg T; Foster R; Krueger P; Garnova E; Rafique A; Babb R; Chen G; Stokes Oristian N; Siao CJ; Daly C; Gurer C; Martin J; Macdonald L; MacDonald D; Poueymirou W; Smith E; Lowy I; Thurston G; Olson W; Lin JC; Sleeman MA; Yancopoulos GD; Murphy AJ; Skokos D
    Sci Transl Med; 2020 Jun; 12(549):. PubMed ID: 32581132
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Bispecific antibodies in multiple myeloma].
    Escure G; Manier S
    Bull Cancer; 2021 Oct; 108(10S):S205-S212. PubMed ID: 34920804
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sequential therapy with inotuzumab ozogamicin, CD19 CAR T cells, and blinatumomab in an elderly patient with relapsed acute lymphoblastic leukemia.
    Wullenkord R; Reicherts C; Mikesch JH; Marx J; Wethmar K; Albring J; Call S; Lenz G; Stelljes M
    Ann Hematol; 2021 Feb; 100(2):587-589. PubMed ID: 32829460
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.